Payment overview · 2025
General Payments
$1,012.46
11 reported records · 6 companies
Healthcare provider profile · identity verified
Ralph Patrick Page, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ROCKLEDGE, FL · NPI 1770569527
Verified facts
What the public records show
CMS Open Payments records show Ralph Patrick Page, M.D. received $1,012.46 in general payments during 2025 across 11 reported records.
Janssen Biotech, Inc. accounted for 41.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Symbicort by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Xarelto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $424.18 | 41.9% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $160.70 | 15.9% | 4 | 2025 |
| Dendreon Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $149.86 | 14.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $124.46 | 12.3% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $124.46 | 12.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.80 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,012.46 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CARVYKTI Normalized: carvykti |
Drug | Janssen Biotech, Inc. | $424.18 | 3 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $424.18 | 3 | 2025 |
Source payment records
|
|||||
| PROVENGE Normalized: provenge |
Drug | Dendreon Pharmaceuticals LLC | $149.86 | 1 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $124.46 | 1 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $124.46 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $120.83 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $39.87 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $28.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
87 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
57 | 17 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone Hcl | Oxycodone Hcl | 1214 | 130 |
| Alprazolam | Alprazolam | 677 | 73 |
| Gabapentin | Gabapentin | 525 | 115 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 467 | 55 |
| Azithromycin | Azithromycin | 422 | 167 |
| Atorvastatin Calcium | Atorvastatin Calcium | 414 | 122 |
| Morphine Sulfate Er | Morphine Sulfate | 402 | 44 |
| Amlodipine Besylate | Amlodipine Besylate | 368 | 94 |
| Prednisone | Prednisone | 322 | 143 |
| Omeprazole | Omeprazole | 320 | 86 |
| Potassium Chloride | Potassium Chloride | 258 | 76 |
| Fluconazole | Fluconazole | 255 | 93 |
| Levothyroxine Sodium | Levothyroxine Sodium | 249 | 73 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 232 | 64 |
| Montelukast Sodium | Montelukast Sodium | 214 | 58 |
| Tizanidine Hcl | Tizanidine Hcl | 214 | 45 |
| Diclofenac Sodium | Diclofenac Sodium | 210 | 64 |
| Metformin Hcl | Metformin Hcl | 205 | 58 |
| Lisinopril | Lisinopril | 204 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 200 | 54 |
| Furosemide | Furosemide | 198 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 176 | 51 |
| Lorazepam | Lorazepam | 168 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 163 | 45 |
| Losartan Potassium | Losartan Potassium | 161 | 44 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 160 | 31 |
| Trazodone Hcl | Trazodone Hcl | 150 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 145 | 25 |
| Carisoprodol | Carisoprodol | 144 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 140 | 25 |
| Ozempic | Semaglutide | 137 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 133 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 132 | 48 |
| Ipratropium Bromide | Ipratropium Bromide | 132 | 45 |
| Amoxicillin | Amoxicillin | 127 | 63 |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 126 | 69 |
| Diazepam | Diazepam | 116 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 112 | 36 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 92 | 62 |
| Carvedilol | Carvedilol | 92 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 90 | 32 |
| Simvastatin | Simvastatin | 90 | 20 |
| Mirtazapine | Mirtazapine | 89 | 16 |
| Sertraline Hcl | Sertraline Hcl | 89 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 88 | 25 |
| Clonazepam | Clonazepam | 87 | 12 |
| Farxiga | Dapagliflozin Propanediol | 87 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 84 | 18 |
| Buspirone Hcl | Buspirone Hcl | 83 | 21 |
| Jardiance | Empagliflozin | 83 | 16 |
| Temazepam | Temazepam | 82 | 12 |
| Alendronate Sodium | Alendronate Sodium | 80 | 18 |
| Linzess | Linaclotide | 80 | 19 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 79 | 16 |
| Levetiracetam | Levetiracetam | 79 | 21 |
| Celecoxib | Celecoxib | 76 | 24 |
| Dicyclomine Hcl | Dicyclomine Hcl | 74 | 20 |
| Eliquis | Apixaban | 72 | 18 |
| Meloxicam | Meloxicam | 72 | 15 |
| Methadone Hcl | Methadone Hcl | 72 | 12 |
| Pregabalin | Pregabalin | 71 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 71 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 68 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 65 | 14 |
| Trulicity | Dulaglutide | 65 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 64 | suppressed |
| Ondansetron Odt | Ondansetron | 62 | 17 |
| Hydromorphone Hcl | Hydromorphone Hcl | 60 | suppressed |
| Atenolol | Atenolol | 57 | 16 |
| Baclofen | Baclofen | 57 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 57 | 17 |
| Naloxone Hcl | Naloxone Hcl | 55 | 39 |
| Bupropion Xl | Bupropion Hcl | 52 | 19 |
| Topiramate | Topiramate | 52 | suppressed |
| Allopurinol | Allopurinol | 50 | 15 |
| Ezetimibe | Ezetimibe | 50 | 19 |
| Mometasone Furoate | Mometasone Furoate | 50 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 28 |
| Clonidine Hcl | Clonidine Hcl | 48 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 14 |
| Naproxen | Naproxen | 47 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 47 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 45 | 13 |
| Famotidine | Famotidine | 45 | 12 |
| Spironolactone | Spironolactone | 45 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 44 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 43 | 18 |
| Methocarbamol | Methocarbamol | 43 | 13 |
| Methylprednisolone | Methylprednisolone | 43 | 42 |
| Tramadol Hcl | Tramadol Hcl | 43 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 31 |
| Doxepin Hcl | Doxepin Hcl | 42 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 11 |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Glipizide | Glipizide | 39 | 13 |
| Entresto | Sacubitril/Valsartan | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 36 | suppressed |
| Oxycontin | Oxycodone Hcl | 35 | suppressed |
| Sumatriptan | Sumatriptan | 35 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | 11 |
| Finasteride | Finasteride | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | 13 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 30 | 13 |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Hydrocortisone | Hydrocortisone | 28 | 18 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 25 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Fentanyl | Fentanyl | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 19 |
| Cefuroxime | Cefuroxime Axetil | 21 | 13 |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 20 | 16 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 14 |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Xtampza Er | Oxycodone Myristate | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Lubiprostone | Lubiprostone | 18 | suppressed |
| Nystatin | Nystatin | 18 | 13 |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 16 | suppressed |
| Epinephrine | Epinephrine | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Desloratadine | Desloratadine | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,012.46 · 11 records | Janssen Biotech, Inc. | AIRSUPRA, BREZTRI, CARVYKTI, Cologuard Collection Kit, LIBTAYO, Nubeqa, PROVENGE, RYBREVANT | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error